VEOZA™
fezolinetant

VEOZA™ (fezolinetant) is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause*[1]

TREAT *the* HEAT
WITH NONHORMONAL VEOZA

NONHORMONAL

VEOZA is a first-in-class selective NK3 receptor antagonist that blocks NKB from binding on KNDy neurons to help reduce heat signals that trigger VMS[2-4]

* See section 5.1 in SmPC

HOW VMS START IN THE HYPOTHALAMUS

Homeostasis
KNDy neurons in the hypothalamus are inhibited by oestrogen and stimulated by the neuropeptide NKB. The balance between inhibition and activation contributes to **body temperature regulation**[3]



Menopause
Oestrogen decline during the menopause transition disrupts the balance between activation by NKB and inhibition by oestrogen. **Unopposed, NKB signalling causes** heightened KNDy neuronal activity. This triggers heat dissipation mechanisms, including vasodilation and sweating – VMS[3]



HOW VEOZA DISRUPTS HOT FLUSHES

Blocking NKB to reduce heat
VEOZA selectively binds to the NK3 receptor to **block NKB** from binding on the KNDy neuron. This action is postulated to restore the balance in KNDy neuronal activity in the thermo-regulatory centre of the hypothalamus[2]



OESTROGEN | OESTROGEN RECEPTOR ALPHA (ERα) | NKB | NK3 RECEPTOR

KNDy=kisspeptin/neurokinin B/dynorphin; NK3=neurokinin 3; NKB=neurokinin B; VMS=vasomotor symptoms

▼ THIS MEDICINAL PRODUCT IS SUBJECT TO ADDITIONAL MONITORING

REDEFINE *how* YOU
TREAT MENOPAUSAL VMS

VEOZA™ (fezolinetant) 45 mg film-coated tablets

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Pharmacotherapeutic group: Other gynaecologicals, ATC code: G02CX06. **Therapeutic indications:** VEOZA is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause (see Section 5.1 in the Summary of Product Characteristics (SmPC)). ***Posology:** Recommended dose is 45 mg once daily. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients; concomitant use of moderate or strong CYP1A2 inhibitors; known or suspected pregnancy. ***Special warnings and precautions for use:** Diagnosis must include medical (including family) history. During treatment, periodic check-ups must be carried out according to standard clinical practice. Is not recommended for use in individuals with Child-Pugh Class B (moderate) or C (severe) chronic hepatic impairment, nor in individuals with severe renal impairment. Monitoring of liver function in women with known or suspected hepatic disorder is advised. VEOZA is not recommended in women undergoing oncologic treatment for breast cancer or other oestrogen-dependent malignancies, nor in women using hormone replacement therapy with oestrogens (local vaginal preparations excluded). Has not been studied in women over 65 years of age, nor in women with a history of seizures or other convulsive disorders. Animal studies have shown reproductive toxicity. ***Undesirable effects:** The listed adverse drug reactions are insomnia, diarrhoea, abdominal pain, and increased alanine aminotransferase (ALT) and aspartate aminotransferase (AST), all with a frequency of less than 10%. **Marketing authorisation holder:** Astellas Pharma Europe B.V., The Netherlands.

Sweden: Status of the product: Rx. **Reimbursement:** No (“EF”). **Local representative:** Astellas Pharma AB, Tel: +46 (0)40 650 15 00. For more information, pack size and price see www.fass.se.

Based on authorised SmPC dated 07 December 2023.

***The section has been rewritten and/or abbreviated compared to the authorised SmPC. The SmPC can be ordered free of charge from the local representative.**

REFERENCES: 1. VEOZA SmPC §4.1 12.2023. **2.** VEOZA SmPC §5.1 12.2023. **3.** Depypere H, Lademacher C, Siddiqui E, Fraser GL. Fezolinetant in the treatment of vasomotor symptoms associated with menopause. Expert Opin Investig Drugs. 2021;30(7):681-94. **4.** Jayasena CN, Comninos AN, Stefanopoulou E, et al. Neurokinin B administration induces hot flushes in women. Sci Rep. 2015;5:8466.

astellas

Astellas Pharma AB | Box 21046 | 200 21 Malmö, Sweden | Phone +46 40 650 1500 | www.astellas.com/se

VEOZA™
fezolinetant

MAT-SE-VEO-2024-00001 | Date of preparation: 03.01.2024